Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Novo Nordisk's GLP-1 receptor agonist semaglutide ... MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects between 6 million to 8 million people in the US alone and for some ...
$ 81.33 0.23 0.28% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback